Articles tagged with Hiv Treatments
Researchers found that Denmark's exceptional treatment programs, with high patient adherence rates, have brought the country's HIV epidemic to near-elimination. The 'treatment as prevention' strategy has been shown to be effective in reducing new infections and can serve as a model for global elimination.
Studies demonstrate that tenofovir alafenamide (TAF) is as effective and safer than tenofovir disoproxil fumarate (TDF) in treating chronic Hepatitis B, with fewer negative changes in bone and kidney parameters. TAF improves patient safety while sustaining efficacy in patients with chronic Hepatitis B virus infection.
Researchers identified six areas for improvement: HIV prevention, common entry points, information availability, funding sources, competiveness, and building trust. Collaboration among agencies was found to be crucial for effective service delivery.
Researchers apply global sensitivity analysis to pinpoint key HIV model parameters affecting treatment plans. By fixing non-influential inputs and minimizing parameter dimensions, they better understand HIV dynamics and develop optimal treatment strategies.
According to a new study from Harvard T.H. Chan School of Public Health, Botswana has achieved remarkable progress in reducing the number of people who are infectious with HIV through strong treatment programs. The country has reported 96% viral suppression rates among patients on antiretroviral therapy, surpassing Western nations and ...
A new study reveals significant racial disparities in treatment for patients with HIV and Hodgkin lymphoma, with black patients facing higher rates of non-treatment. Despite effective treatment options, doctors note that socioeconomic factors and lack of access to care may contribute to these disparities.
A new study by the University of Liverpool's Institute of Infection and Global Health has found HIV infection to be the leading risk factor for stroke in young African adults. The incidence of stroke is increasing across sub-Saharan Africa, with many cases occurring in young adults with low prevalence of established risk factors.
A five-year, $60 million project will integrate HIV services with tuberculosis, malaria, family planning, nutrition, and other health services. The project aims to increase the availability, accessibility, and quality of health services for vulnerable populations in southwestern Uganda.
Young men with HIV who have sex with men are more likely to report condomless anal sex, particularly with a partner not infected with HIV. Behavioral approaches to improve engagement in care and medication adherence may need to occur in concert with interventions to reduce risky sexual behaviors.
Three large clinical trials provide compelling data on the benefits of starting antiretroviral therapy (ART) early in HIV infection, outweighing theoretical risks. The results also show that pre-exposure prophylaxis (PrEP) significantly reduces HIV transmission among high-risk populations.
A modeling study suggests that countries will likely miss the 90-90-90 treatment target by 2020 due to funding gaps. The estimated gap in financial resources needed versus available for ART scale-up ranges from $19.8 billion to $25.0 billion.
Late-treatment HIV patients with low CD4 levels progress to AIDS at high rates if immune response isn't recovered. However, if viral load is undetectable and CD4 counts rise above 200, mortality and progression decrease.
A University of Georgia researcher found that low levels of vitamin D can hinder the effectiveness of HIV treatment in adults. Participants with sufficient vitamin D levels recovered more of their immune function, on average 65 CD4+T cells more, compared to those with deficiency.
A study found that switching to efavirenz-based therapy did not result in higher rates of viral rebound or failure in HIV-infected children with suppressed viral loads. This approach may offer advantages in these patients.
The LA BioMed's Catalina Island Clinic has received a $10,000 grant to provide confidential, free, and no-cost reproductive health care services to uninsured women and adolescent girls. The clinic offers a range of services, including family planning, STI testing, and counseling.
A primary care-based program has been shown to lower patients' substance dependence and encourage treatment engagement. The program's success was attributed to medication-assisted treatment, such as buprenorphine, and addressing underlying depression.
Researchers found marginalized Vancouver residents are dying at 8.29 times the national average, with psychosis and hepatitis C-related liver dysfunction being significant risk factors for mortality. The study highlights the need for improved detection and treatment of these conditions in marginalized populations.
A project in Togo saw a 10% drop in TB death rates by increasing the treatment success rate to 95%, while mortality dropped from 13% to 3%. The redesigned system improved coverage, quality, and patient participation, highlighting the importance of data analysis and skilled workforce.
Three teams of undergraduate students won the National Institutes of Health's Design by Biomedical Undergraduate Teams (DEBUT) Challenge with projects focused on improving global health. The winners developed a portable HIV treatment monitor, a surgical clamp to treat drooping eyelids, and a low-cost patient monitor.
A recent study found that HIV virus can persist and continue to grow in patients receiving uninterrupted treatment for up to 14 years. This persistence occurs due to the virus's ability to hide inside blood cells responsible for immune response, copy itself, and automatically incorporate its genetic information into DNA.
The improved survival rate of HIV patients in sub-Saharan Africa facilitates the study of cardiovascular disease in these patients. Studies have shown that highly active antiretroviral treatment is associated with a 50% reduction in HIV-related cardiomyopathy, and researchers now have access to a population with both HIV and cardiovasc...
Canada has eliminated mother-to-child HIV transmission by ensuring all pregnant women are screened for HIV and receive treatment. Regular combination antiretroviral therapy (cART) is nearly 100% effective in preventing transmission when given during pregnancy.
New research finds that HIV treatment for illicit drug users promotes improved health, socio-economic stability, and quality of life. Consistent ART treatment reduces homelessness and involvement in activities like sex work or street-based income generation.
A new study found that starting antiretroviral therapy early reduces the risk of both serious AIDS-related events and serious non-AIDS-related events, including cancer, cardiovascular disease, and death. The study shows a significant benefit of early treatment regardless of age, sex, or geographic region.
The HPTN 052 study demonstrates that early antiretroviral therapy significantly reduces HIV transmission in serodiscordant couples, with a sustained 93% reduction when the HIV-infected partner is on treatment and viral load suppressed. The trial also found that timely ART initiation can lead to improved health outcomes.
A decade-long NIH-funded trial found that antiretroviral therapy consistently suppresses HIV, greatly reducing sexual transmission to uninfected partners. The study demonstrates the enduring power of HIV-controlling treatment in protecting heterosexuals from transmission.
A study found that starting anti-HIV treatment within two weeks of TB diagnosis improved survival rates among patients with very low CD4 T-cell counts. However, delaying treatment until after TB is completed may be beneficial for patients with stronger immune systems.
A new national study found that most states violate federal Medicaid law by denying coverage for sofosbuvir, a highly effective treatment for hepatitis C. The study highlights the need to improve access to treatment for low-income and underserved patients.
A major international trial found that starting antiretroviral drugs earlier reduces the risk of developing AIDS and other serious illnesses. The study supported treating everyone with HIV, regardless of CD4+ T-cell count.
A new study has found high levels of hepatitis C (HCV) infection across Africa, particularly in people infected with HIV. The report, published in The Lancet Infectious Diseases, found that around three per cent of people in sub-Saharan Africa have been infected with HCV infection, rising to 5.7 per cent in individuals with HIV.
The millennium development goals have made remarkable progress in areas such as child mortality reduction and HIV prevention. However, significant shortfalls remain in other areas, including newborn death rates and undernutrition.
Researchers found that the human immune system can control re-awakened HIV with a vaccine-based approach, reducing virus levels to 50 copies per ml within six weeks. This study demonstrates the potential of a 'kick and kill' strategy, which could lead to an effective cure for HIV.
A new study simulates Cabo Verde's public health using a computer model to predict the spread of disease and the efficacy of interventions. The results suggest that accelerating four efforts already underway across the country could reduce annual new HIV cases below 10 per 10,000 residents.
A new study published in the journal AIDS found that for most children with HIV and low immune cell counts, cells rebound after treatment. The researchers analyzed data from over 3,700 children infected with HIV before or during birth and found that 86% of children achieved normal CD4+ counts within one year of treatment.
Implementing video-based decision aids in urology led to fewer elective surgeries for benign prostatic hyperplasia and localized prostate cancer. Rates of surgical intervention declined by 32% for treated BPH patients and 27% for localized prostate cancer patients.
A new TB drug regimen, PaMZ, has shown promising results in a Phase 2b clinical trial, demonstrating the potential to treat both drug-sensitive and multidrug-resistant TB in four to six months. The regimen, comprising pretomanid and moxifloxacin, was found to be effective independent of HIV status.
A study estimates that undiagnosed HIV individuals and those diagnosed but not in medical care accounted for over 90% of the estimated 45,000 HIV transmissions in 2009. These individuals were 19-94% less likely to transmit HIV than those with viral suppression.
Brown University professors Joseph Hogan and Rami Kantor will use a new $3.5 million grant to develop data-driven methods for improving HIV treatment monitoring decisions, potentially reducing costs and increasing effectiveness in low- and middle-income countries.
A new study suggests that starting HIV treatment within a year of seroconversion can improve immune health by increasing CD4+ T-cell count. Researchers found that an HIV-infected person's CD4+ T-cell count is more likely to return to normal if treatment starts within a year and at a CD4+ T-cell count of 500 or more.
The first article suggests that physicians can steer eligible defendants into treatment programs instead of correctional facilities, while the second article advocates for fair hiring practices in hospitals to improve the health and wellbeing of former inmates. Both articles emphasize the importance of addressing social issues such as ...
A Phase III clinical study has been initiated in Ethiopia to assess the efficacy and safety of two treatment combinations for HIV-visceral leishmaniasis co-infected patients. The study aims to identify a safe and effective treatment for this life-threatening condition, which affects millions worldwide.
A team of researchers reports a case of a baby born with HIV who appeared to be cured after early antiretroviral treatment, but later exhibited detectable HIV infection. The child's immune system showed signs of responding to HIV even after the virus was undetectable.
A new licensing agreement between Medicines Patent Pool and Gilead Sciences could improve treatment options for children living with HIV. The deal will allow generic versions of the medication tenofovir alafenamide fumarate (TAF) to be developed in India and China for countries with over 92% of people living with HIV.
A study published in JAMA found that HIV-infected patients with hepatitis C virus (HCV) infection who received a combination of sofosbuvir plus ribavirin achieved high rates of sustained HCV virologic response after therapy cessation. The treatment showed promise for coinfection, which affects up to 7 million worldwide.
Experts from the London School of Hygiene & Tropical Medicine and UNHCR call for equal access to HIV treatment for refugees and internally displaced persons in stable settings. The authors recommend routine adherence monitoring systems and point-of-care laboratory monitoring to ensure high levels of viral suppression.
A new study suggests that testing for sexually transmitted infections (STIs) when testing for HIV can improve HIV prevention efforts in South Africa and the broader region. The study found that patients with HIV were more likely to contract STIs before starting treatment, highlighting the importance of simultaneous STI detection and tr...
A new paper highlights the disproportionate impact of HIV on communities of color and poor neighborhoods, emphasizing the need for geographically targeted prevention and treatment efforts. The authors call for increased investment in vulnerable communities to combat the epidemic.
A study of 882 HIV-infected prisoners found that treating inmates for HIV while incarcerated helped a majority achieve viral suppression by release. Most prisoners achieved viral suppression regardless of age, race, or ART regimen type.
The Affordable Care Act (ACA) has a profound impact on vulnerable Americans living with HIV/AIDS, significantly reducing the transmission of the disease and improving treatment outcomes. Early treatment initiation is crucial in preventing new cases and mortality, with estimated cost savings of $80 billion from 1996 to 2009.
A computer model recommends a combination of interventions, including increased HIV testing, substance abuse treatment, needle and syringe exchange programs, and antiretroviral treatment as prevention to reduce HIV spread in NYC. The result would lower new infections by more than 60% by 2040.
The university's AIDS Clinical Trials Unit will conduct human studies to advance knowledge of HIV-related diseases, prevention, and treatment. The award supports the development of effective methods to prevent HIV infection and fine-tune treatments for patients, aiming to improve life expectancy and quality of life.
A major South African trial failed to reduce TB cases or deaths among gold miners. Researchers highlight the need for a combination prevention approach with better tests and prompt treatment to control the disease.
A new community program, SHE PREVAILS, is helping African-American women reduce their risk of HIV infection by addressing substance abuse and mental health issues. The program provides six-month comprehensive treatment and support services to 280 women in the Augusta region.
A recent study identified a population of stem-like T memory cells where HIV persists despite treatment. These cells have the ability to regenerate new HIV-infected cells, fueling the virus's persistence in the human body. The findings suggest that targeting these cells could lead to novel interventions for future treatment.
A new study found that antiretroviral therapy has saved 2.8 million years of life in South Africa since 2004, with projections of an additional 15.1 million years saved by 2030. Aggressive HIV testing and treatment strategies could further increase these benefits.
Researchers have identified a molecular invisibility cloak that enables HIV to hide in cells, but exposing it triggers an immune response. This discovery could lead to new treatments and improve existing therapies for HIV infection.
A 3-year-old Mississippi child born with HIV continues to show no signs of active infection 18 months after stopping treatment. The case suggests that prompt antiviral therapy may help infants clear the virus and achieve long-term remission, potentially paving the way for a sterilizing HIV cure.
The V-SmartTM therapeutic delivered tenofovir at levels considerably above therapeutic concentrations, overcoming the challenge of delivering HIV drugs through the BBB. The successful outcome confirms the strong potential of the delivery system to treat neuro-HIV and improve lives of AIDS patients.
A new study published in PLOS Medicine suggests that South Africa's current antiretroviral treatment policy could lead to HIV elimination within the next 24-34 years. The research also found that a universal test and treat approach could achieve elimination 10 years earlier, according to more comprehensive mathematical models.
The trial aims to assess whether treating HIV-infected individuals as a form of prevention can substantially reduce new HIV infections across communities. The study will measure the impact on 52,500 adults over three years in 21 communities with a population of 1.2 million.